Page 70 - லுட்விக் அதிகபட்சம் பல்கலைக்கழகம் முனிச் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal of the American Academy of Ophthalmology, Ophthalmology ® gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper , published in the January issue under the title, “Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset”, is the second peer-reviewed article based on Phase III clinical trial data to document comparable bilateral improvement in visual outcomes from a unilateral injection of a gene therapy.

New yorkUnited statesWills eye hospitalFrance generalUnited kingdomThomas jefferson universityCity ofUniversity hospitalEmory university school of medicineMagali taielClinica neurologicaPiero barboniBarrett katzCatherine vignal clermontLaure blouinAlfredoa sadun